spla2 inhibitors

Details spla2 inhibitors spla2 inhibitors

2002-12-03

2004-03-30

Lambkin, Deborah C (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C549S051000

Reexamination Certificate

active

06713505

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to novel benzo(b)thiophene compounds useful for Inflammatory Diseases.
BACKGROUND OF THE INVENTION
The structure and physical properties of human non-pancreatic secretory phospholipase A
2
(hereinafter called, “sPLA
2
”) has been thoroughly described in two articles, namely, “Cloning and Recombinant Expression of Phospholipase A
2
Present in Rheumatoid Arthritic Synovial Fluid” by Seilhamer, Jeffrey J.; Pruzanski, Waldemar; Vadas Peter; Plant, Shelley; Miller, Judy A.; Kloss, Jean; and Johnson, Lorin K.;
The Journal of Biological Chemistry,
Vol. 264, No. 10, Issue of April 5, pp. 5335-5338, 1989; and “Structure and Properties of a Human Non-pancreatic Phospholipase A
2
” by Kramer, Ruth M.; Hession, Catherine; Johansen, Berit; Hayes, Gretchen; McGray, Paula; Chow, E. Pingchang; Tizard, Richard; and Pepinsky, R. Blake;
The Journal of Biological Chemistry,
Vol. 264, No. 10, Issue of April 5, pp. 5768-5775, 1989; the disclosures of which are incorporated herein by reference.
It is believed that sPLA
2
is a rate limiting enzyme in the arachidonic acid cascade which hydrolyzes membrane phospholipids. Thus, it is important to develop compounds, which inhibit sPLA
2
mediated release of fatty acids (e.g., arachidonic acid). Such compounds would be of value in general treatment of conditions induced and/or maintained by overproduction of sPLA
2
; such as sepsis or rheumatoid arthritis.
It is desirable to develop new compounds and treatments for sPLA
2
induced diseases.
SUMMARY OF THE INVENTION
This invention provides novel benzo(b)thiophene compounds having potent and selective effectiveness as inhibitors of mammalian sPLA
2
.
This invention is also the use of novel benzo(b)thiophene compounds useful in the treatment and/or prevention of Inflammatory Diseases.
This invention is also the use of novel benzo(b)thiophene compounds to inhibit mammalian sPLA
2
mediated release of fatty acids.
This invention is also a pharmaceutical composition containing any of the benzo(b)thiophene compounds of the invention.
I. Definitions
The term, “Inflammatory Diseases” refers to diseases such as inflammatory bowel disease, sepsis, septic shock, adult respiratory distress syndrome, pancreatitis, trauma-induced shock, asthma, bronchial asthma, allergic rhinitis, rheumatoid arthritis, cystic fibrosis, stroke, acute bronchitis, chronic bronchitis, acute bronchiolitis, chronic bronchiolitis, osteoarthritis, gout, spondylarthropathris, ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, enteropathric spondylitis, Juvenile arthropathy or juvenile ankylosing spondylitis, Reactive arthropathy, infectious or post-infectious arthritis, gonoccocal arthritis, tuberculous arthritis, viral arthritis, fungal arthritis, syphilitic arthritis, Lyme disease, arthritis associated with “vasculitic syndromes”, polyarteritis nodosa, hypersensitivity vasculitis, Luegenec's granulomatosis, polymyalgin rheumatica, joint cell arteritis, calcium crystal deposition arthropathris, pseudo gout, non-articular rheumatism, bursitis, tenosynomitis, epicondylitis (tennis elbow), carpal tunnel syndrome, repetitive use injury (typing), miscellaneous forms of arthritis, neuropathic joint disease (charco and joint), hemarthrosis (hemarthrosic), Henoch-Schonlein Purpura, hypertrophic osteoarthropathy, multicentric reticulohistiocytosis, arthritis associated with certain diseases, surcoilosis, hemochromatosis, sickle cell disease and other hemoglobinopathries, hyperlipoproteineimia, hypogammaglobulinemia, hyperparathyroidism, acromegaly, familial Mediterranean fever, Behat's Disease, systemic lupus erythrematosis, or relapsing polychondritis and related diseases which comprises administering to a mammal in need of such treatment a therapeutically effective amount of the compound of formula I in an amount sufficient to inhibit sPLA
2
mediated release of fatty acid and to thereby inhibit or prevent the arachidonic acid cascade and its deleterious products.
The terms, “benzo(b)thiophene”, “benzothiophene, or “benzo(b)thiophene” nucleus as used herein refer to a nucleus (having numbered positions) with the structural formula (X):
The benzo(b)thiophene compounds of the invention employ certain defining terms as follows:
The term, “alkyl” by itself or as part of another substituent means, unless otherwise defined, a straight or branched chain monovalent hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, tertiary butyl, sec-butyl, n-pentyl, and n-hexyl.
The term, “alkenyl” employed alone or in combination with other terms means a straight chain or branched monovalent hydrocarbon group having the stated number ranges of carbon atoms, and typified by groups such as vinyl, propenyl, crotonyl, isopentenyl, and various butenyl isomers.
The term, “hydrocarbyl” means an organic group containing only carbon and hydrogen.
The term, “halo” means fluoro, chloro, bromo, or iodo.
The term, heterocyclic radical, refers to radicals derived from monocyclic or polycyclic, saturated or unsaturated, substituted or unsubstituted heterocyclic nuclei having 5 to 14 ring atoms and containing from 1 to 3 hetero atoms selected from the group consisting of nitrogen, oxygen or sulfur. Typical heterocyclic radicals are pyrrolyl, pyrrolodinyl, piperidinyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, benzo(b)thiophenyl, carbazolyl, norharmanyl, azabenzo(b)thiophenyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, indazolyl, imidazo(1.2-A)pyridinyl, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl, benzothiazolyl, purinyl, pyridinyl, dipyridylyl. phenylpyridinyl, benzylpyridinyl, pyrimidinyl, phenylpyrimidinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl, phthalazinyl, quinazolinyl, morpholino, thiomorpholino, homopiperazinyl, tetrahydrofuranyl, tetrahydropyranyl, oxacanyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrahydrothiophenyl, pentamethylenesulfadyl, 1,3-dithianyl, 1,4-dithianyl, 1,4-thioxanyl, azetidinyl, hexamethyleneiminium, heptamethyleneiminium, piperazinyl and quinoxalinyl.
The term, “carbocyclic radical” refers to radicals derived from a saturated or unsaturated, substituted or unsubstituted 5 to 14 membered organic nucleus whose ring forming atoms (other than hydrogen) are solely carbon atoms. Typical carbocyclic radicals are cycloalkyl, cycloalkenyl, phenyl, spiro[5.5]undecanyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenylyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzylyl and related bibenzylyl homologues represented by the formula (a):
where n is a number from 1 to 8.
The term, “non-interfering substituent”, refers to radicals suitable for substitution at positions 4,5,6 and/or 7 of the benzo(b)thiophene nucleus and on other nucleus substituents (as hereinafter described for Formula I), and radicals suitable for substitution on the heterocyclic radical and carbocyclic radical as defined above. Illustrative non-interfering radicals are C
1
-C
8
alkyl, C
2
-C
8
alkenyl, C
2
-C
8
alkynyl, C
7
-C
12
aralkyl, C
7
-C
12
alkaryl, C
3
-C
8
cycloalkyl, C
3
-C
8
cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl, C
1
-C
8
alkoxy, C
2
-C
8
alkenyloxy, C
2
-C
8
alkynyloxy, C
2
-C
12
alkoxyalkyl, C
2
-C
12
alkoxyalkyloxy, C
2
-C
12
alkylcarbonyl, C
2
-C
12
alkylcarbonylamino, C
2
-C
12
alkoxyamino, C
2
-C
12
alkoxyaminocarbonyl, C
1
-C
12
alkylamino, C
1
-C
6
alkylthio, C
2
-C
12
alkylthiocarbonyl, C
1
-C
8
alkylsulfinyl, C
1
-C
8
alkylsulfonyl, C
2
-C
8
haloalkoxy, C
1
-C
8
haloalkylsulfonyl, C
2
-C
8
haloalkyl, C
1
-C
8
hydroxyalkyl, —C(O)O(C
1
-C
8
alkyl), —(CH
2
)
n
—O—(C
1
-C
8
alkyl), benzyloxy, phenoxy, phenylthio, —(CONHSO
2
R), —CHO, amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy, —(CH
2
)
n
—CO
2
H, chloro, cyano, cyanoguanidinyl, fluoro, guanidino, hydrazide, hydrazino, hydrazido, hydroxy, hydroxyamino, iodo, nitro, phosphono, —SO
3
H,

Affiliated with

Also associated with

Rating

spla2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with spla2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and spla2 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3197754